<DOC>
	<DOCNO>NCT02861534</DOCNO>
	<brief_summary>This randomize , placebo-controlled , parallel-group , multi-center , double-blind , event driven study vericiguat ( MK-1242 ) participant HFrEF . The primary hypothesis vericiguat ( MK-1242 ) superior placebo increase time first occurrence composite cardiovascular ( CV ) death heart failure ( HF ) hospitalization participant HFrEF .</brief_summary>
	<brief_title>A Study Vericiguat Participants With Heart Failure With Reduced Ejection Fraction ( HFrEF ) ( MK-1242-001 )</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<criteria>History chronic HF ( New York Heart Association [ NYHA ] Class IIIV ) standard therapy qualify HF decompensation Previous HF hospitalization within 6 month prior randomization intravenous ( IV ) diuretic treatment HF ( without hospitalization ) within 3 month . Brain natriuretic peptide ( BNP ) level : sinus rhythm≥ 300 pg/mL ; atrial fibrillation≥ 500 pg/mL Nterminal proBrain Natriuretic Peptide ( NTproBNP ) level : sinus rhythm ≥ 1000 pg/mL ; atrial fibrillation ≥ 1600 pg/mL within 30 day prior randomization Left ventricular ejection fraction ( LVEF ) &lt; 45 % assess within 12 month prior randomization method If female , reproductive potential agree avoid become pregnant receiving study drug 14 day last dose study drug comply one following : practice abstinence heterosexual activity use ( partner use ) acceptable contraception heterosexual activity . Clinically unstable time randomization define either administration IV treatment within 24 hour prior randomization , and/or systolic blood pressure ( SBP ) &lt; 100 mmHg symptomatic hypotension Current anticipate use longacting nitrate nitric oxide ( NO ) donor include isosorbide dinitrate , isosorbide 5mononitrate , pentaerythritol tetranitrate , nicorandil transdermal nitroglycerin ( NTG ) patch , molsidomine Current anticipate use phosphodiesterase type 5 ( PDE5 ) inhibitor vardenafil , tadalafil , sildenafil Current use anticipate use soluble guanylate cyclase ( sGC ) stimulator riociguat Known allergy sensitivity sGC stimulator Awaiting heart transplantation ( United Network Organ Sharing Class 1A / 1B equivalent ) , receive continuous IV infusion inotrope , has/anticipates receive implant ventricular assist device Primary valvular heart disease require surgery intervention , within 3 month valvular surgery intervention Hypertrophic obstructive cardiomyopathy Acute myocarditis , amyloidosis , sarcoidosis , Takotsubo cardiomyopathy Postheart transplant cardiomyopathy Tachycardiainduced cardiomyopathy and/or uncontrolled tachyarrhythmia Acute coronary syndrome ( unstable angina , nonST elevation myocardial infarction [ NSTEMI ] , ST elevation myocardial infarction [ ( STEMI ] ) coronary revascularization ( coronary artery bypass graft [ CABG ] percutaneous coronary intervention [ PCI ] ) within 60 day , indication coronary revascularization time randomization Symptomatic carotid stenosis , transient ischemic attack ( TIA ) stroke within 60 day Complex congenital heart disease Active endocarditis constrictive pericarditis Estimated glomerular filtration rate ( eGFR ) &lt; 15 mL/min/1.73 m2 chronic dialysis Severe hepatic insufficiency hepatic encephalopathy Malignancy noncardiac condition limit life expectancy &lt; 3 year Require continuous home oxygen severe pulmonary disease Current alcohol and/or drug abuse Participated another interventional clinical study treatment another investigational product ≤30 day prior randomization plan participate trial/investigation duration study Mental legal incapacitation unable provide inform consent Immediate family member ( e.g. , spouse , parent/legal guardian , sibling child ) involve study Interstitial Lung Disease Breastfeeding plan breastfeed course study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>